Barclays PLC grew its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 110.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,862 shares of the company's stock after purchasing an additional 40,416 shares during the quarter. Barclays PLC owned about 0.13% of Harmony Biosciences worth $3,074,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in Harmony Biosciences by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company's stock worth $80,000 after buying an additional 360 shares in the last quarter. Profund Advisors LLC increased its stake in shares of Harmony Biosciences by 11.1% in the 2nd quarter. Profund Advisors LLC now owns 7,557 shares of the company's stock worth $228,000 after acquiring an additional 758 shares during the last quarter. CWM LLC increased its stake in shares of Harmony Biosciences by 111.7% in the 3rd quarter. CWM LLC now owns 1,469 shares of the company's stock worth $59,000 after acquiring an additional 775 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Harmony Biosciences by 0.7% during the 2nd quarter. AQR Capital Management LLC now owns 154,345 shares of the company's stock worth $4,657,000 after acquiring an additional 1,116 shares during the period. Finally, nVerses Capital LLC acquired a new position in shares of Harmony Biosciences during the 2nd quarter valued at about $36,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have weighed in on HRMY. Needham & Company LLC reiterated a "buy" rating and issued a $52.00 target price on shares of Harmony Biosciences in a report on Tuesday, October 29th. Cantor Fitzgerald increased their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 30th. Oppenheimer restated an "outperform" rating and issued a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Raymond James reiterated an "outperform" rating and set a $40.00 price target on shares of Harmony Biosciences in a report on Thursday, October 10th. Finally, Mizuho boosted their price objective on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an "outperform" rating in a report on Thursday, October 10th. Two analysts have rated the stock with a sell rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, Harmony Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $49.80.
Check Out Our Latest Stock Report on Harmony Biosciences
In other Harmony Biosciences news, insider Jeffrey Dierks sold 21,496 shares of the stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $40.47, for a total value of $869,943.12. The transaction was disclosed in a document filed with the SEC, which is available at this link. 30.80% of the stock is currently owned by company insiders.
NASDAQ HRMY opened at $34.95 on Tuesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The company has a market cap of $1.99 billion, a P/E ratio of 16.56, a P/E/G ratio of 0.60 and a beta of 0.79. The stock has a 50-day moving average of $34.23 and a two-hundred day moving average of $34.19. Harmony Biosciences Holdings, Inc. has a 1-year low of $28.14 and a 1-year high of $41.61.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.15. The firm had revenue of $186.00 million for the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm's revenue for the quarter was up 16.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.63 EPS. As a group, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current year.
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.